Modulation Of Cd4+ T Cell Responses By A Tick Saliva Protein, Salp15 And Polypeptides Derived Therefrom
AssigneeThe University of North Carolina at Charlotte
InventorJuan Anguita
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe University of North Carolina at Charlotte
InventorJuan Anguita
Estimating the term…
Salp15, biologically functional equivalents and fragments thereof, and nucleic acid molecules encoding the same are disclosed. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed. Salp15 gene products and Salp15 polypeptide fragments have biological activity in modulating CD4+ T cell activation through specific binding to CD4. Thus, therapeutic methods involving modulating T cell activation using Salp15 and biologically active polypeptide fragments thereof are also disclosed. The specific binding of Salp15 and fragment peptides thereof to CD4 can inhibit HIV infection of T cells, and thus methods of using Salp15 for inhibiting HIV infection are also disclosed. Screening methods for selecting substances having an ability to modulate activation of T cells are also disclosed.
An isolated and purified biologically active Salp15 polypeptide, comprising:
An isolated nucleic acid molecule, comprising:
A method of modulating activation of a CD4+ T cell due to T cell receptor-mediated signaling, comprising contacting the T cell with a Salp15 polypeptide comprising:
A method of treating a subject suffering from or at risk of suffering from a condition characterized by a CD4+ T cell response, comprising administering to the subject an effective amount of a Salp15 polypeptide comprising:
A method of treating multiple sclerosis in a subject, comprising administering to the subject an effective amount of a Salp15 polypeptide, or a biologically active fragment thereof, having immunosuppressive activity to the subject.
A method of inhibiting infection of a T cell by a human immunodeficiency virus (HIV), comprising contacting a CD4 receptor expressed by the T cell with a Salp15 polypeptide, or a biologically active fragment thereof having binding specificity for the CD4 receptor, whereby contacting the Salp15 polypeptide with the CD4 receptor inhibits the HIV from infecting the T cell.
A method of screening a candidate substance for an ability to modulate activation of a CD4+ T cell, the method comprising:
Dependencies are inferred from the claim text.